Clinical Trial Search

Primary: Liver Fibrosis Response After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis — 0.24; 0.25; 0.27; 0.23 score on a…

Primary: Change in Minute Ventilation 5 Minutes From Opioid Induced Nadir — 4.42; 2.03 L/min

Primary: Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Treatment Period: Change From Baseline in Latency to Persistent Sleep (LPS) on Day 30 of Lemborexant 5 mg Compared to Placebo — -46.12; -50.90 minutes — p=0.0133

Primary: Participation in Tobacco Cessation Treatment — 9; 29 Participants

Primary: Molecular Diagnostic qPCR Comparison of DBI-002 Drug Product and Malassezia (Fungal Cause of Tinea Versicolor) — 2; 4; 5; 1 Participants — p=0.2

Primary: Change in Maximum Excursion — 80.9; 86.5; 66.8; 80.9 percentage of center of pressure motion

Primary: Part 1: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Arm 4) — 6; 9; 8; 0 Participants

Primary: Effect of DOT Diary App on PrEP Adherence — 39; 19 Participants — p=0.94

Primary: The Number of Caregivers Who Complete the Checklist — 28 Participants

Primary: Treatment Acceptability Questionnaire (TAQ) — 5.7; 6.4 score on a scale

Primary: Change in Cortical Activation — 0.054; -0.024; 0.074; -0.016 Unitless GLM beta weight (HbO) — p=0.007

Primary: Occurrence of Unsolicited Adverse Events (AEs), According to the Medical Dictionary for Regulatory Activities (MedRA) Classification. — 17; 6; 4 Participants

Primary: Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1) — -61.5; -56.8; -51.6; -59.6 percentage of change — p=<0.0001

Primary: Change in Hand Strength During Intervention and at Follow-up. — 24; 23 KG